Vnitr Lek 2005, 51(1):77-81

Dyslipidemia and metabolic syndrome

V. Soška
Centrum pro diagnostiku a léčbu dyslipidemií, Oddělení klinického komplementu FN u sv. Anny, Brno, přednosta doc. MUDr. Vladimír Soška, CSc.

Dyslipidemia is common part of the metabolic syndrome. The typical lipid disorders are hypertrigylceridemia and low HDL-cholesterol. Elevation of small LDL3 and apolipoprotein B100 are also present in most patients. Weight reduction, diet and regular physical activity are the most effective way how to treat this type of dyslipoproteinemia. Before hypolipidemic drug therapy is started, type of dyslipidemia must be considered. Fibrates are recommended in patients with hypertriglyceridemia and low HDL-cholesterol. When high LDL-cholesterol is present, statin therapy is recommended. In some patients therapy with both fibrate and statin is needed to reach target lipid levels.

Keywords: dyslipidemia; metabolic syndrome; HDL-cholesterol; triglycerides; LDL3

Received: January 12, 2004; Accepted: July 15, 2004; Published: January 1, 2005  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Soška V. Dyslipidemia and metabolic syndrome. Vnitr Lek. 2005;51(1):77-81.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Assmann G, Schulte H, von Eckardstein A. Hypertriglyceridemia and elevated lipoprotein(a) are risk factors for major coronary events in middle-aged men. Am J Cardiol 1996; 77: 1179-1184. Go to original source... Go to PubMed...
    2. Austin MA, Hokanson JE, Edwards KL. Hypertriglyceridemia as a cardiovascular risk factor. Am J Cardiol1998; 81 (4A): 7B-12B. Go to original source... Go to PubMed...
    3. Castelli WP. Epidemiology of triglycerides: a view from Framingham. Am J Cardiol 1992; 70: 3H-9H. Go to original source... Go to PubMed...
    4. Cífková R et al. Prevence ischemické choroby srdeční v dospělém věku. Vnitř Lék 2000; 46 (Suppl. 14): 14-20. Go to PubMed...
    5. Češka R. Cholesterol a ateroskleróza. Praha: Maxdorf 1999.
    6. De Graaf J, Veerkamp MJ, Stalenhoef AF. Metabolic pathogenesis of familial combined hyperlipidaemia with emphasis on insulin resistance, adipose tissue metabolism and free fatty acids. J Royal Soc Med 2002; 95 (Suppl. 42): 46-53.
    7. Eisenberg S. High-density lipoprotein metabolism. In: Betteridge DJ, Illingworth DR (Eds.): Lipoproteins in health and disease. London: Arnold 1999.
    8. European guidelines on cardiovascular disease prevention in clinical practice. Third joint task force of European and other societies on cardiovascular disease prevention in clinical practice. Eur Heart J 2003; 24: 1601-1610.
    9. Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults: Executive summary of the third report of the National cholesterol education program (NCEP) expert panel of detection, evaluation, and treatment of high blood cholesterol in adults (Adult treatment panel III). JAMA 2001; 285 (19): 2486-2497. Go to PubMed...
    10. Frick MH, Elo O, Haapa K et al. Helsinky Heart Study: Primary prevention trial with gemfibrozil in middle aged men with dyslipidemia. N Engl J Med 1987; 317: 1237-1245. Go to original source... Go to PubMed...
    11. Gibbons GF, Brown AM, Wiggins D et al. The role of insulin and fatty acids in the regulation of hepatic very-low-density lipoprotein assambly. J Royal Soc Med 2002; 95 (Suppl 42): 23-32.
    12. Griffin J et al. Role of plasma triglyceride in the regulation of plasma low density lipoprotein (LDL) subfractions: relative contribution of small, dense LDL to coronary heart disease risk. Atherosclerosis 1994; 106: 241-253. Go to original source... Go to PubMed...
    13. Jančík J, Svačinová H, Dobšák P et al. Kombinovaný trénink u nemocných se systolickou dysfunkcí levé komory srdeční. Vnitř Lék 2003; 49(4): 280-284. Go to PubMed...
    14. Manninen V, Tenkanen L, Koskinen P et al. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentration on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment. Circulation 1992; 85: 37-45. Go to original source... Go to PubMed...
    15. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360: 7-22.
    16. Pocock SJ, Shaper AG, Philips AN. HDL-cholesterol triglycerides and total cholesterol in ischemic heart disease. Br Med J 1989; 298: 998-1002. Go to original source... Go to PubMed...
    17. Prevention of Coronary Heart Disease in Clinical Practice. Summary of Recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention, 1998.
    18. Rubins HB, Robins SJ, Collins D et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med 1999; 341: 410-418. Go to original source... Go to PubMed...
    19. Sacks FM. For the Expert Group on HDL cholesterol: The role of high-density lipoprotein (HDL) cholesterol in the prevention and treatment of coronary heart disease: Expert group recommendations. Am J Cardiol 2000; 90: 139-142. Go to original source... Go to PubMed...
    20. Saxena U, Witte LD, Goldberg IJ. Release of endothelial lipoprotein lipase by plasma lipoproteins and free fatty acid. J Biol Chem 1989; 264: 4349-4355. Go to original source...
    21. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 pateints with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 334: 1383-1389. Go to original source...
    22. Shepherd J, Cobbe SM, Ford I. et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Prevention Study Group. N Engl J Med 1995; 333: 1301-1307. Go to original source... Go to PubMed...
    23. Soška V. Poruchy metabolizmu lipidů: Diagnostika a léčba. Praha: Grada 2001.
    24. Van Harmelen V, Reynosdottir S, Cianflone K et al. Mechanisms involved in the regulation of free fatty acid release from isolated human fat cells by acylation stimulating protein and insulin. J Biol Chem 1999; 274: 18243-18251. Go to original source... Go to PubMed...
    25. Weber, P, Kocourková B, Dočekalová A et al. Hyperlipidemie - možnosti léčby u diabetiků typu II. Geriatria 1999; 3-4: 115-122.
    26. Zeman M, Žák A, Tvrzická E et al. Vliv fibrátů na složení lipoproteinů VLDL a LDL a parametry jejich oxidace u hypertriglyceridémie. Čas Lék Čes 2002; 7(141): 211-216.
    27. Zilversmit DB. Atherosclerosis: a postprandial phenomen. Circulation 1979; 60: 473-485. Go to original source... Go to PubMed...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.